Wockhardt shares slip after drug recall in US

Shares of Mumbai-based Wockhardt Ltd have fallen down following company's recall of anti-hypertensive drug from the US market. Wockhardt is recalling about bottles of anti-hypertensive drug, Metoprolol, belonging to multiple lots from the American market following failure of dissolution test, US health regulator FDA said.

Shares were closed at Rs 776.45, down by 2.36% on BSE.  Shares were slipped by 3%  at Rs 770.65 intraday on Thursday. Metoprolol is a generic version of AstraZeneca’s branded drug Toprol. Tablet dissolution is a standardised method for measuring the rate of drug release from a dosage form.

According to a notification by the US Food and Drug Administration (USFDA), the recall is voluntary and was initiated by the company from April 1 under Class-II classification.
 

Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Metoprolol Succinate Extended-Release Tablets were distributed in the USA by Wockhardt USA.